USPTO Examiner HOLMES REX R - Art Unit 3796

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18760208REDUCING ELEVATED INTRAOCULAR PRESSURE VIA A STIMULATION ELECTRODE ASSEMBLYJuly 2024March 2025Allow910NoNo
18670220TISSUE EXTRACTION DEVICES AND METHODSMay 2024June 2025Allow1320NoNo
18646184SYSTEM AND METHOD FOR ELECTROCARDIOGRAM ANALYSIS AND OPTIMIZATION OF CARDIOPULMONARY RESUSCITATION AND THERAPY DELIVERYApril 2024June 2025Allow1310YesNo
18643195MEDICAL MONITORING DEVICE FOR HARMONIZING PHYSIOLOGICAL MEASUREMENTSApril 2024May 2025Allow1210NoNo
18629125SYSTEMS AND METHODS FOR TREATING MYOCARDIAL CONDITIONSApril 2024December 2024Allow820YesNo
18618822Methods for Reducing the Risk of Heart Failure or Strokes by Pharmacotherapy to Reduce the Number and Duration of Atrial FibrillationsMarch 2024December 2024Allow920NoNo
18439536SUBCUTANEOUS DEVICEFebruary 2024January 2025Allow1110NoNo
18424631METHOD AND SYSTEM FOR ALTERING BODY MASS COMPOSITION USING GALVANIC VESTIBULAR STIMULATIONJanuary 2024April 2025Allow1510YesNo
18542883EJACULATION CONTROLDecember 2023January 2025Allow1310NoNo
18536344SYSTEMS AND METHODS OF DELIVERING THERAPY USING AN AMBULATORY MEDICAL DEVICEDecember 2023July 2025Allow1920NoNo
18388383IMPELLER FOR BLOOD PUMPNovember 2023April 2025Allow1710NoNo
18383575Intravenous / Intra-Spinal / Intra-Cavity / Intraventricular Delivery of TTFields (Tumor Treating Fields) for Treating Cancer and MetastasesOctober 2023November 2024Allow1301YesNo
18376727Methods for Reducing the Risk of Strokes by Pharmacotherapy to Reduce the Number and Duration of Atrial FibrillationsOctober 2023June 2024Allow810NoNo
18459044VACUUM LOSS DETECTION DURING LASER EYE SURGERYAugust 2023November 2024Allow1410NoNo
18224638APPARATUS, SYSTEM AND OPERATION METHOD FOR THE TREATMENT OF FEMALE SEXUAL DYSFUNCTIONJuly 2023December 2024Allow1720NoNo
18222621Methods for Reducing the Risk of Strokes by Pharmacotherapy to Reduce the Number and Duration of Atrial FibrillationsJuly 2023January 2024Allow610YesNo
18212844Heart Beat Identification and Pump Speed SynchronizationJune 2023October 2024Allow1510NoNo
18205015MICROWAVE ABLATION SYSTEMJune 2023June 2025Abandon2510NoNo
18318313APPARATUS AND METHODS FOR RESECTING AND/OR ABLATING AN UNDESIRED TISSUEMay 2023August 2024Allow1610NoNo
18313444INTRA-CARDIAC MAPPING AND ABLATINGMay 2023December 2024Allow1920YesNo
18308561MEDICAL SYSTEM AND METHOD OF USEApril 2023July 2024Allow1410NoNo
18080115PERSONALIZED HEART RHYTHM THERAPYDecember 2022March 2025Allow2711NoNo
17938595PERSONALIZED AVATAR RESPONSIVE TO USER PHYSICAL STATE AND CONTEXTOctober 2022July 2024Allow2210NoNo
17951175SYSTEM AND METHOD FOR AN ELECTRICAL IMPLANT DEVICE WITH INCREASED PATIENT COMPLIANCESeptember 2022May 2025Allow3120NoNo
17902836Diagnosis of medical conditions using voice recordings and auscultationSeptember 2022September 2024Allow2420YesNo
17897480SUBCUTANEOUS IMPLANTABLE DEFIBRILLATOR WITH EPICARDIAL LEAD FOR RESYNCHRONIZATION THERAPYAugust 2022September 2024Abandon2410NoNo
17894765INTEGRATED PROBE STRUCTUREAugust 2022May 2025Allow3321YesNo
17819108MOBILE DEFIBRILLATORAugust 2022December 2024Allow2820YesNo
17813739ENERGY CONVERSION MONITORING DEVICES AND METHODSJuly 2022July 2024Allow2420NoNo
17812974SYSTEM AND METHOD FOR SENSING AND DETECTION IN AN EXTRA-CARDIOVASCULAR IMPLANTABLE CARDIOVERTER DEFIBRILLATORJuly 2022December 2024Allow2910YesNo
17864983STIMULATION PROBE ASSEMBLIES AND METHODS OF USEJuly 2022September 2024Allow2610YesNo
17856946MULTI-THRESHOLD SENSING OF CARDIAC ELECTRICAL SIGNALS IN AN EXTRACARDIOVASCULAR IMPLANTABLE CARDIOVERTER DEFIBRILLATORJuly 2022February 2025Allow3110YesNo
17851236METHOD AND DEVICE FOR MANAGING PACING THERAPY BASED ON INTERVENTRICULAR SEPTAL ACTIVITYJune 2022April 2024Allow2210NoNo
17850987OPHTHALMIC TREATMENT DEVICE, METHOD FOR CONTROLLING OPHTHALMIC TREATMENT DEVICE, AND FUNDUS LESION TREATMENT METHODJune 2022June 2024Allow2310NoNo
17838128LIGHT-BASED NON-INVASIVE BLOOD PRESSURE SYSTEMS AND METHODSJune 2022July 2024Allow2611YesNo
17806124PERSONALIZED AVATAR RESPONSIVE TO USER PHYSICAL STATE AND CONTEXTJune 2022August 2024Allow2620YesNo
17806120PERSONALIZED AVATAR RESPONSIVE TO USER PHYSICAL STATE AND CONTEXTJune 2022July 2024Allow2620NoNo
17806117PERSONALIZED AVATAR RESPONSIVE TO USER PHYSICAL STATE AND CONTEXTJune 2022July 2024Allow2520YesNo
17748533System And Method For Predicting Tissue IntegrityMay 2022March 2025Allow3421YesNo
17740333ELECTROCARDIOGRAM METHOD FOR LACTATE THRESHOLD DETECTIONMay 2022November 2023Allow1900NoNo
17720439SMART WRISTBAND FOR MULTIPARAMETER PHYSIOLOGICAL MONITORINGApril 2022February 2025Allow3410YesNo
17768329METHODS AND SYSTEMS FOR MODULATING CELLULAR ACTIVATIONApril 2022May 2025Allow3721YesNo
17717864IMPLANTABLE DEVICE HAVING ONE OR MORE SCREWSApril 2022December 2024Abandon3201NoNo
17767647Implantable Medical DeviceApril 2022February 2024Allow2240YesNo
17641753PACEMAKER DEVICEMarch 2022July 2024Allow2820NoNo
17679450APPARATUS AND METHOD FOR TREATMENT OF DRY EYESFebruary 2022April 2025Abandon3840NoYes
17675903DEVICES AND METHODS TO MEASURE GASTRIC RESIDUAL VOLUMEFebruary 2022June 2024Allow2810NoNo
17675944Comprehensive Second-Language Acquisition System Leveraging Sleep Neuromodulation and Neuroaugmented Executive ControlFebruary 2022January 2025Allow3530NoNo
17669294DEVICE AND METHOD FOR ATRIAL TACHYARRHYTHMIA DETECTIONFebruary 2022January 2025Allow3620YesNo
17587223TISSUE EXTRACTION DEVICES AND METHODSJanuary 2022February 2024Allow2520NoNo
17565747DEVICE AND METHOD FOR TREATING DRY EYESDecember 2021March 2025Allow3811NoNo
17552813MANAGING THERAPY DELIVERY BASED ON PHYSIOLOGICAL MARKERSDecember 2021September 2024Allow3310NoNo
17542776STIMULUS COIL AND PULSE GENERATOR FOR WIRELESS GLAUCOMA THERAPYDecember 2021February 2024Allow2610NoNo
17541075VENTRICULAR BLANKING PERIOD AFTER ATRIALLY SENSED BEATSDecember 2021September 2024Allow3310YesNo
17528721SYSTEM FOR IDENTIFYING AND REMEDIATING PATIENT WITHDRAWAL SYMPTOMSNovember 2021October 2024Allow3520YesNo
17607711SYSTEMS AND METHODS FOR QUANTITATIVE ECG HETEROGENEITY-GUIDED OPTIMIZATION OF THERAPEUTIC EFFICACY OF IMPLANTABLE CARDIAC DEVICESOctober 2021September 2024Abandon3410NoNo
17498402Defibrillation Through Synchronous Multisite PacingOctober 2021September 2024Abandon3510NoNo
17495644DEEP TREATMENT DRESSINGSOctober 2021January 2025Abandon3940NoNo
17493539GUIDING ANTI-TACHYARRHYTHMIA PACING TRAIN DESIGN AND ELECTRODE SELECTION WITH ELECTROGRAMSOctober 2021May 2024Allow3210YesNo
17465673CURRENT STEERING FOR CARDIAC PACINGSeptember 2021January 2025Allow4031YesNo
17459338SURGICAL TOOL FOR ROBOTIC SURGERY AND ROBOTIC SURGICAL ASSEMBLYAugust 2021April 2025Allow4310YesNo
17406411REDUCING ELECTROCARDIOGRAM ARTIFACTS DURING AND POST CPRAugust 2021June 2024Allow3420YesNo
17445214CHARGE COMPENSATION CIRCUIT FOR NEURAL STIMULATIONAugust 2021April 2024Allow3210NoNo
17445215PULSE CURRENT GENERATION CIRCUITAugust 2021April 2024Allow3210YesNo
17400648ADAPTIVE CALIBRATION FOR SENSOR-EQUIPPED ATHLETIC GARMENTSAugust 2021July 2024Abandon3510NoNo
17393989APPARATUS AND METHOD FOR NERVE ABLATION IN THE WALL OF THE GASTOINTESTINAL TRACTAugust 2021August 2024Abandon3710NoNo
17389047PERSONALIZED AVATAR RESPONSIVE TO USER PHYSICAL STATE AND CONTEXTJuly 2021January 2024Allow2920NoNo
17382217SYSTEMS AND METHODS OF ANALYTE MEASUREMENT ANALYSISJuly 2021October 2024Allow3930YesNo
17304605SYSTEMS AND METHODS FOR DETECTING FAULT CONDITIONS IN ELECTROPORATION THERAPYJune 2021August 2024Allow3720NoNo
17415303INTRAORAL NEUROMODULATIONJune 2021June 2025Allow4821YesNo
17344745SUBCUTANEOUS DEVICEJune 2021September 2023Allow2820YesNo
17344731METHOD OF INJECTING SUBCUTANEOUS DEVICEJune 2021August 2023Allow2700NoNo
17337530MODULATE PACING RATE TO INCREASE THE PERCENTAGE OF EFFECTIVE VENTRICULAR CAPTURE DURING ATRIAL FIBRILLATIONJune 2021November 2023Allow2920YesNo
17328928PATIENT MONITORING AND TREATMENT SYSTEMS AND METHODSMay 2021December 2023Allow3111YesNo
17324705DEVICES, METHODS, AND SYSTEMS FOR THE TREATMENT AND/OR MONITORING OF DAMAGED TISSUEMay 2021February 2024Allow3330YesNo
17324396MEDICAL MONITORING DEVICE FOR HARMONIZING PHYSIOLOGICAL MEASUREMENTSMay 2021February 2024Allow3220YesNo
17318014APPARATUS FOR ENDO FISTULA LASER THERAPYMay 2021February 2024Abandon3320NoNo
17181605IMPLANTABLE STIMULATING ASSEMBLYFebruary 2021August 2024Allow4221YesYes
17165129METHODS, SYSTEM AND DEVICE FOR IMPROVING CARDIAC RESYNCHRONIZATION THERAPY (CRT)February 2021October 2023Allow3211NoNo
17248488HEALTH TRACKING DEVICEJanuary 2021June 2024Allow4131YesNo
17129467NEUROSTIMULATION TITRATION UTILIZING T-WAVE ALTERNANSDecember 2020May 2024Allow4021YesNo
17054882METHOD AND DEVICE FOR PROCESSING PHYSIOLOGICAL DATA, AND STORAGE MEDIUMNovember 2020October 2024Abandon4720NoNo
17090259HUMAN BIOELECTRICAL SIGNAL DETECTION AND MONITORINGNovember 2020December 2023Allow3710NoNo
17050702MULTI-SENSOR BASED HMI/AI-BASED SYSTEM FOR DIAGNOSIS AND THERAPEUTIC TREATMENT OF PATIENTS WITH NEUROLOGICAL DISEASEOctober 2020March 2024Abandon4110NoNo
17061513SYSTEM AND METHOD FOR ELECTROCARDIOGRAM ANALYSIS AND OPTIMIZATION OF CARDIOPULMONARY RESUSCITATION AND THERAPY DELIVERYOctober 2020January 2024Allow4021YesNo
17035157AV NODAL STIMULATION DURING ATRIAL TACHYARRHYTHMIA TO PREVENT INAPPROPRIATE THERAPY DELIVERYSeptember 2020September 2023Allow3610NoNo
17024885SYSTEMS AND METHODS OF DELIVERING THERAPY USING AN AMBULATORY MEDICAL DEVICESeptember 2020September 2023Allow3620YesNo
16957164ON-BED STATE MONITORING SYSTEM AND BED INCLUDING SAMEAugust 2020April 2024Allow4670YesNo
16941085BRAIN STIMULATION THERAPYJuly 2020November 2023Allow3940YesNo
16924990ANALYZING ECAP SIGNALSJuly 2020November 2023Allow4140YesNo
16957752EJACULATION CONTROLJune 2020September 2023Allow3930YesNo
16772883MULTI-LAYER STRUCTURE, SYSTEM, USE AND METHODJune 2020September 2024Abandon5140YesNo
16897171METHODS FOR TREATMENT OF DISEASE USING GALVANIC VESTIBULAR STIMULATIONJune 2020October 2023Allow4030NoYes
16767768STORING A SIGNAL TO A MEMORYMay 2020November 2023Allow4230YesNo
16724518METHOD AND SOFTWARE TO DETERMINE PROBABILITY OF SLEEP/WAKE STATES AND QUALITY OF SLEEP AND WAKEFULNESS FROM AN ELECTROENCEPHALOGRAMDecember 2019April 2024Abandon5230NoYes
16677893VENA-CAVAL BLOOD PUMPNovember 2019October 2023Allow4741YesNo
16660212METHODS AND DEVICES FOR CONTROLLING ABLATION THERAPYOctober 2019May 2023Allow4330YesNo
16585344ADHESIVELY COUPLED WEARABLE MEDICAL DEVICESeptember 2019October 2023Allow4922YesNo
16573606WEARABLE CARDIAC MONITORSeptember 2019June 2023Allow4521YesNo
16358123MANUFACTURING METHOD FOR A MULTIELECTRODE SYSTEMMarch 2019June 2024Allow6060YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HOLMES, REX R.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
2
Examiner Affirmed
2
(100.0%)
Examiner Reversed
0
(0.0%)
Reversal Percentile
19.8%
Lower than average

What This Means

With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
7
Allowed After Appeal Filing
1
(14.3%)
Not Allowed After Appeal Filing
6
(85.7%)
Filing Benefit Percentile
15.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 14.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner HOLMES, REX R - Prosecution Strategy Guide

Executive Summary

Examiner HOLMES, REX R works in Art Unit 3796 and has examined 121 patent applications in our dataset. With an allowance rate of 87.6%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 33 months.

Allowance Patterns

Examiner HOLMES, REX R's allowance rate of 87.6% places them in the 63% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.

Office Action Patterns

On average, applications examined by HOLMES, REX R receive 2.04 office actions before reaching final disposition. This places the examiner in the 67% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by HOLMES, REX R is 33 months. This places the examiner in the 30% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +17.6% benefit to allowance rate for applications examined by HOLMES, REX R. This interview benefit is in the 63% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 30.8% of applications are subsequently allowed. This success rate is in the 53% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 42.4% of cases where such amendments are filed. This entry rate is in the 58% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 21% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 66.7% of appeals filed. This is in the 47% percentile among all examiners. Of these withdrawals, 50.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 0.0% are granted (fully or in part). This grant rate is in the 6% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 3.3% of allowed cases (in the 84% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 5.7% of allowed cases (in the 81% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.